Huntingtons Disease

Huntington Disease - Pipeline Review, H1 2018

Mon, 03 Sep 2018 14:10:02 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H1 2018, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action ...

$2,000.00

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

Mon, 10 Oct 2016 12:19:19 +0000

Huntington’s Disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired motor control, cognitive dysfunction, behavioral changes, and mood disorders. Approved treatments for HD across the 7MM are extremely limited, consisting of only two symptomatic treatments, tetrabenazine and tiapride, which are both approved for the treatment of HD-associated chorea. Other treatment options contributing to the HD market are off-label symptomatic drugs, many of which are widely genericized throughout the 7MM. Four late-stage pipeline drugs, two symptomatic treatments (SD-809 and pridopidine) and two potential DMDs (RP103 and PBT2) are expected to launch in the US and 5EU markets during the forecast period, and will be a source of significant growth in the HD market. It is anticipated that SD-809 and pridopidine will also launch in Japan within the forecast period....

$10,995.00

Huntington's Disease-Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Huntington’s Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Huntington’s Disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Huntington’s Disease forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Huntington’s Disease till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Huntington’s Disease market. • Identifying patient populations in the global “Huntington’s Disease market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Huntington’s Disease the...

$4,950.00

Huntington Disease Global Clinical Trials Review, H1, 2016

Sun, 19 Jun 2016 18:32:13 +0000

Summary

GlobalData's clinical trial report, “Huntington Disease Global Clinical Trials Review, H1, 2016" provides an overview of Huntington Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Huntington Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain co...

$2,500.00

Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016

Wed, 01 Jun 2016 20:02:25 +0000

Summary

Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Huntingtin (Huntington Disease Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Huntingtin (Huntington Disease Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary da...

$3,500.00